Form 4: Phathom Pharmaceuticals Director Receives RSUs

Theodore R. Schroeder, a Director at Phathom Pharmaceuticals, Inc., was granted Restricted Stock Units (RSUs) representing 24,122 shares of common stock.

Summary

• Theodore R. Schroeder, a Director of Phathom Pharmaceuticals, Inc., received a grant of 24,122 Restricted Stock Units (RSUs) on May 19, 2026.
• These RSUs are part of the Issuer's Non-Employee Director Compensation Program.
• The RSUs will vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, provided Mr. Schroeder continues to serve on the Board.
• Each RSU represents a contingent right to receive one share of Phathom Pharmaceuticals' common stock.
• Following this transaction, Mr. Schroeder beneficially owns 45,122 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard director compensation event rather than a significant financial or strategic development.

Positives

• Director compensation through equity awards like RSUs can align management interests with shareholder value.
• The vesting schedule encourages continued service and commitment to the company's long-term success.

Risks

• The value of the RSUs is subject to the future performance and stock price of Phathom Pharmaceuticals.
• Vesting is contingent on continued service, meaning any departure before vesting would result in forfeiture of the unvested RSUs.

Future Outlook

The RSUs are subject to vesting conditions, with full vesting occurring on the first anniversary of the grant date or the next annual stockholder meeting, contingent on continued service.

Industry Context

StockSavvy.ai notes that the issuance of RSUs to directors is a common practice in the biopharmaceutical industry to attract and retain experienced leadership, aligning their incentives with long-term company performance and shareholder returns.

Stakeholder Impact

• Shareholders: The grant of RSUs is a form of compensation and does not immediately impact share count, but future share issuance upon vesting will dilute existing shareholders. The alignment of director incentives may positively impact long-term shareholder value.
• Employees: This filing does not directly impact employees.
• Creditors: This filing does not directly impact creditors.
• Suppliers: This filing does not directly impact suppliers.
• Customers: This filing does not directly impact customers.

Next Steps

• Vesting of RSUs on the first anniversary of the grant date or the next annual stockholder meeting, subject to continued service.

Key Dates

Keywords

Phathom Pharmaceuticals, PHAT, Form 4, SEC Filing, Director Compensation, Restricted Stock Units, RSUs, Equity Award, Beneficial Ownership